Allergan's most recent trend suggests a bearish bias. One trading opportunity on Allergan is a Bear Call Spread using a strike $230.00 short call and a strike $237.50 long call offers a potential 50% return on risk over the next 23 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $230.00 by expiration. The full premium credit of $2.50 would be kept by the premium seller. The risk of $5.00 would be incurred if the stock rose above the $237.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Allergan is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Allergan is bearish.
The RSI indicator is at 38.7 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
Hedge Funds Are Cashing Out Of These Stocks As Investors Yank Capital
Tue, 25 Oct 2016 14:03:35 GMT
KYBELLA® (deoxycholic acid) injection 10 mg/mL Puts “Profiles in Focus” With Expert Panel And New Direct-To-Consumer Campaign
Tue, 25 Oct 2016 12:30:00 GMT
PR Newswire – DUBLIN, Oct. 25, 2016 /PRNewswire/ — Studies show that more than two-thirds of aesthetically-oriented consumers are bothered by submental fullness, or “double chin.”1 And with social media profile images becoming more important than ever, there is interest in looking one's best.
Allergan Successfully Completes Vitae Tender Offer
Tue, 25 Oct 2016 12:01:05 GMT
noodls – DUBLIN, Oct. 25, 2016 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the successful completion of Allergan's tender offer to purchase all outstanding …
Allergan Successfully Completes Vitae Tender Offer
Tue, 25 Oct 2016 11:46:00 GMT
PR Newswire – DUBLIN, Oct. 25, 2016 /PRNewswire/ — Allergan plc (AGN), a leading global pharmaceutical company, today announced the successful completion of Allergan's tender offer to purchase all outstanding shares of Vitae Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on innovative development programs for dermatologic conditions. As previously announced, Allergan offered to purchase all outstanding shares of Vitae for $21.00 per share, in cash, for a total transaction value of approximately $639 million. The acquisition strengthens Allergan's dermatology product pipeline, with the addition of VTP-43742, a Phase 2 first-in-class, orally active RORγt (retinoic acid receptor-related orphan receptor gamma) inhibitor for the potential treatment of psoriasis and other autoimmune disorders.
Cramer says the hottest theme on Wall Street is thanks to…
Mon, 24 Oct 2016 22:25:00 GMT
Related Posts
Also on Market Tamer…
Follow Us on Facebook